• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺素E2通过依赖蛋白激酶A的途径激活造血祖细胞激酶1的激酶活性。

Prostaglandin E2 activates HPK1 kinase activity via a PKA-dependent pathway.

作者信息

Sawasdikosol Sansana, Pyarajan Saiju, Alzabin Saba, Matejovic Gabriel, Burakoff Steven J

机构信息

New York University School of Medicine, New York University Cancer Institute, New York, New York 10016-6402, USA.

出版信息

J Biol Chem. 2007 Nov 30;282(48):34693-9. doi: 10.1074/jbc.M707425200. Epub 2007 Sep 25.

DOI:10.1074/jbc.M707425200
PMID:17895239
Abstract

Hematopoietic progenitor kinase 1 (HPK1) is a hematopoietic cell-restricted member of the Ste20 serine/threonine kinase super family. We recently reported that the immunosuppressive eicosanoid, prostaglandin E(2) (PGE(2)), is capable of activating HPK1 in T cells. In this report, we demonstrate that unlike the TCR-induced activation of HPK1 kinase activity, the induction of HPK1 catalytic activity by PGE(2) does not require the presence of phosphotyrosine-based signaling molecules such as Lck, ZAP-70, SLP-76, and Lat. Nor does the PGE(2)-induced HPK1 activation require the intermolecular interaction between its proline-rich regions and the SH3 domain-containing adaptor proteins, as required by the signaling from the TCR to HPK1. Instead, our study reveals that PGE(2) signal to HPK1 via a 3' -5 '-cyclic adenosine monophosphate-regulated, PKA-dependent pathway. Consistent with this observation, changing the serine 171 residue that forms the optimal PKA phosphorylation site within the "activation loop" of HPK1 to alanine completely prevents this mutant from responding to PGE(2)-generated stimulation signals. Moreover, the inability of HPK1 to respond to PGE(2) stimulation in PKA-deficient S49 cells further supports the importance of PKA in this signaling pathway. We speculate that this unique signaling pathway enables PGE(2) signals to engage a proven negative regulator of TCR signal transduction pathway and uses it to inhibit T cell activation.

摘要

造血祖细胞激酶1(HPK1)是Ste20丝氨酸/苏氨酸激酶超家族中造血细胞限制性成员。我们最近报道,免疫抑制类花生酸前列腺素E2(PGE2)能够激活T细胞中的HPK1。在本报告中,我们证明,与TCR诱导的HPK1激酶活性激活不同,PGE2诱导的HPK1催化活性不需要基于磷酸酪氨酸的信号分子如Lck、ZAP-70、SLP-76和Lat的存在。PGE2诱导的HPK1激活也不需要其富含脯氨酸区域与含SH3结构域的接头蛋白之间的分子间相互作用,而TCR向HPK1的信号传导则需要这种相互作用。相反,我们的研究表明,PGE2通过3'-5'-环磷酸腺苷调节的、PKA依赖的途径向HPK1发出信号。与这一观察结果一致,将HPK1“激活环”内形成最佳PKA磷酸化位点的丝氨酸171残基突变为丙氨酸,完全阻止了该突变体对PGE2产生的刺激信号作出反应。此外,在PKA缺陷的S49细胞中HPK1无法对PGE2刺激作出反应,进一步支持了PKA在该信号通路中的重要性。我们推测,这种独特的信号通路使PGE2信号能够与TCR信号转导通路中已证实的负调节因子结合,并利用它来抑制T细胞激活。

相似文献

1
Prostaglandin E2 activates HPK1 kinase activity via a PKA-dependent pathway.前列腺素E2通过依赖蛋白激酶A的途径激活造血祖细胞激酶1的激酶活性。
J Biol Chem. 2007 Nov 30;282(48):34693-9. doi: 10.1074/jbc.M707425200. Epub 2007 Sep 25.
2
Involvement of hematopoietic progenitor kinase 1 in T cell receptor signaling.造血祖细胞激酶1在T细胞受体信号传导中的作用。
J Biol Chem. 2001 Jun 1;276(22):18908-14. doi: 10.1074/jbc.M101485200. Epub 2001 Mar 13.
3
The adaptor protein Gads (Grb2-related adaptor downstream of Shc) is implicated in coupling hemopoietic progenitor kinase-1 to the activated TCR.衔接蛋白Gads(Shc下游与Grb2相关的衔接蛋白)参与将造血祖细胞激酶-1与活化的T细胞受体偶联。
J Immunol. 2000 Aug 1;165(3):1417-26. doi: 10.4049/jimmunol.165.3.1417.
4
Hematopoietic progenitor kinase 1 (HPK1) negatively regulates prostaglandin E2-induced fos gene transcription.造血祖细胞激酶1(HPK1)负向调节前列腺素E2诱导的fos基因转录。
Blood. 2003 May 1;101(9):3687-9. doi: 10.1182/blood-2002-07-2316. Epub 2003 Jan 9.
5
Protein phosphatase 4 is a positive regulator of hematopoietic progenitor kinase 1.蛋白磷酸酶4是造血祖细胞激酶1的正向调节因子。
J Biol Chem. 2004 Nov 19;279(47):49551-61. doi: 10.1074/jbc.M410317200. Epub 2004 Sep 13.
6
HPK1 is activated by lymphocyte antigen receptors and negatively regulates AP-1.HPK1 被淋巴细胞抗原受体激活,并对 AP-1 进行负调控。
Immunity. 2000 Apr;12(4):399-408. doi: 10.1016/s1074-7613(00)80192-2.
7
Activation of hematopoietic progenitor kinase 1 involves relocation, autophosphorylation, and transphosphorylation by protein kinase D1.造血祖细胞激酶1的激活涉及蛋白激酶D1介导的重新定位、自身磷酸化和转磷酸化。
Mol Cell Biol. 2005 Mar;25(6):2364-83. doi: 10.1128/MCB.25.6.2364-2383.2005.
8
Leukocyte-specific adaptor protein Grap2 interacts with hematopoietic progenitor kinase 1 (HPK1) to activate JNK signaling pathway in T lymphocytes.白细胞特异性衔接蛋白Grap2与造血祖细胞激酶1(HPK1)相互作用,以激活T淋巴细胞中的JNK信号通路。
Oncogene. 2001 Mar 29;20(14):1703-14. doi: 10.1038/sj.onc.1204224.
9
Prostaglandin E2 activates cAMP response element-binding protein in glioma cells via a signaling pathway involving PKA-dependent inhibition of ERK.前列腺素 E2 通过涉及 PKA 依赖性 ERK 抑制的信号通路在神经胶质瘤细胞中激活 cAMP 反应元件结合蛋白。
Prostaglandins Other Lipid Mediat. 2010 Feb;91(1-2):18-29. doi: 10.1016/j.prostaglandins.2009.12.002. Epub 2009 Dec 14.
10
SH2/SH3 adaptor proteins can link tyrosine kinases to a Ste20-related protein kinase, HPK1.SH2/SH3衔接蛋白可将酪氨酸激酶与一种Ste20相关蛋白激酶HPK1连接起来。
J Biol Chem. 1997 Oct 31;272(44):27804-11. doi: 10.1074/jbc.272.44.27804.

引用本文的文献

1
HPK1 kinase inhibitor: a sufficient approach to target HPK1 to modulate T cell activation in cancer immunotherapy compared with degraders.HPK1激酶抑制剂:与降解剂相比,靶向HPK1以调节癌症免疫治疗中T细胞活化的一种有效方法。
Front Immunol. 2025 Feb 6;16:1449106. doi: 10.3389/fimmu.2025.1449106. eCollection 2025.
2
An updated review of small-molecule HPK1 kinase inhibitors (2016-present).小分子HPK1激酶抑制剂的最新综述(2016年至今)。
Future Med Chem. 2024;16(22):2431-2450. doi: 10.1080/17568919.2024.2420630. Epub 2024 Nov 25.
3
HPK1 citron homology domain regulates phosphorylation of SLP76 and modulates kinase domain interaction dynamics.
HPK1 柠檬酸基结构域调节 SLP76 的磷酸化,调节激酶结构域相互作用动态。
Nat Commun. 2024 May 2;15(1):3725. doi: 10.1038/s41467-024-48014-9.
4
Small molecule inhibitors for cancer immunotherapy and associated biomarkers - the current status.小分子抑制剂在癌症免疫治疗及相关生物标志物中的应用现状。
Front Immunol. 2023 Oct 31;14:1297175. doi: 10.3389/fimmu.2023.1297175. eCollection 2023.
5
The expanding role for small molecules in immuno-oncology.小分子在肿瘤免疫治疗中的作用不断扩大。
Nat Rev Drug Discov. 2022 Nov;21(11):821-840. doi: 10.1038/s41573-022-00538-9. Epub 2022 Aug 18.
6
Discovery of Novel HPK1 Inhibitors Through Structure-Based Virtual Screening.通过基于结构的虚拟筛选发现新型HPK1抑制剂。
Front Pharmacol. 2022 Mar 14;13:850855. doi: 10.3389/fphar.2022.850855. eCollection 2022.
7
Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds.作为临床前免疫治疗工具化合物的二氨基嘧啶甲酰胺HPK1抑制剂的发现。
ACS Med Chem Lett. 2021 Mar 19;12(4):653-661. doi: 10.1021/acsmedchemlett.1c00096. eCollection 2021 Apr 8.
8
Mechanism of Na-K-ATPase Inhibition by PGE2 in Intestinal Epithelial Cells.前列腺素 E2(PGE2)抑制肠道上皮细胞钠钾-ATP 酶的机制。
Cells. 2021 Mar 29;10(4):752. doi: 10.3390/cells10040752.
9
Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function.抑制造血祖细胞激酶 1 可正向调节 T 细胞功能。
PLoS One. 2020 Dec 3;15(12):e0243145. doi: 10.1371/journal.pone.0243145. eCollection 2020.
10
A perspective on HPK1 as a novel immuno-oncology drug target.HPK1 作为一种新型免疫肿瘤学药物靶点的观点。
Elife. 2020 Sep 8;9:e55122. doi: 10.7554/eLife.55122.